4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole → 2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-amine

Participants

Role	Name	HCID	Charge
Reactant	4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole	HCID 45480186	—
Reactant	Tert-butyl 2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-ylcarbamate	HCID 59592872	—
Product	2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-amine	HCID 59592924	—

Reaction Steps

Tert-butyl 2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-ylcarbamate (50 mg) was coupled to 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 7 via General Procedure A. The product was purified by reverse phase HPLC to yield 8.8 mg of 225. MS (Q1) 353 (M)+

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US07846929B2
Source dataset	uspto-grants-2010_12
ORD ID	ord-eab789c965774d33b4b191f42980fedb
Source note	uspto-grants-2010_12